GlassScriptPhysician profile
Kami J Maddocks
NPI 1689698284
$236,250.37
in general payments reported to CMS, 2019-2025
26 companies · $48K in 2025
The $48K reported for 2025 was more than what 93% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $7,245 · 2021: $18K · 2022: $40K · 2023: $46K · 2024: $56K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $123K · Honoraria: $12K · Travel and Lodging: $12K · Food and Beverage: $3,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $123,399.75 |
| Honoraria | $11,900.00 |
| Travel and Lodging | $11,801.70 |
| Food and Beverage | $3,209.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $44,806.98 | 2022-2025 | |
| Abbvie INC. | $30,019.89 | 2022-2025 | |
| Lilly USA, LLC | $26,102.41 | 2022-2024 | Jaypirca |
| Celgene Corporation | $21,162.45 | 2019-2023 | |
| Genentech USA, INC. | $18,756.49 | 2019-2025 | Columvi, Lunsumio, Polivy |
| Incyte Corporation | $14,967.54 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $13,864.67 | 2022-2025 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $12,858.50 | 2022-2025 | |
| Eli Lilly and Company | $10,008.79 | 2021-2024 | Jaypirca |
| Genentech, INC. | $6,625.00 | 2023 | Polivy |
| Genmab U.S., INC. | $6,437.68 | 2023-2024 | Epkinly |
| Merck Sharp & Dohme LLC | $4,880.00 | 2023-2024 | |
| Astrazeneca Uk Limited | $4,761.57 | 2019-2025 | Calquence |
| Seagen INC. | $4,184.86 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $3,888.54 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $3,590.00 | 2020-2021 | |
| Beigene USA, INC. | $2,275.00 | 2020-2021 | |
| Daiichi Sankyo INC. | $2,257.50 | 2022 | |
| Epizyme, INC. | $1,687.50 | 2021 | |
| Beone Medicines USA, INC. | $1,600.00 | 2025 | Brukinsa |
| Janssen Scientific Affairs, LLC | $1,515.00 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kami Maddocks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.